FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to compounds of the formula (I): wherein Ar1 means heterocyclic group representing pyrazole that can be substituted with one or some radicals R1,R2 or R3; Ar2 means phenyl, naphthyl or tetrahydronaphthyl being each of them is substituted optionally with one-three groups R2; L means saturated or unsaturated branched or linear carbon C1-C10-chain wherein one or some methylene groups are replaced optionally with oxygen atom, NH or sulfur atom and wherein a binding group is substituted optionally with 0-2 oxo-groups; Q has values taken among the order: (a) phenyl, naphthyl, pyridine, imidazole, pyrane and so on; (b) tetrahydropyrane, morpholine, thiomorpholine, thiomorpholine sulfoxide and so on; (c) secondary or tertiary amino-group wherein nitrogen atom of amino-group is bound covalently with groups taken among C1-C3-alkyl, and C1-C5-alkoxyalkyl; R1 has values taken among the row: (a) branched or linear C3-C10-alkyl and so on; (b) C3-C7-cycloalkyl and so on, or tetrahydropyrane group; R2 represents branched or linear C1-C6-alkyl that can be halogenated partially or completely; R3 is taken among the row including: (a) phenyl, naphthyl and heterocyclic group representing pyridinyl and so on; (b) branched or linear (C1-C6)-alkyl that can be halogenated partially or completely and that can be substituted with phenyl group; R4 and R5 mean morpholine; X means oxygen atom; and to their physiologically acceptable salts and acids. Invention proposes method for preparing compounds of the formula (I). Also, invention proposes pharmaceutical composition inhibiting producing cytokines comprising compound by cl. 1 or its pharmaceutically acceptable derivatives as an active substance and usual adjuvants. Invention proposes methods for treatment of inflammatory and autoimmune disease that involve administration to patient needing treatment compound by cl. 1 taken in therapeutically effective amount. Invention provides preparing aromatic heterocyclic compounds as anti- -inflammatory agents. EFFECT: valuable medicinal properties of compounds. 17 cl, 16 sch, 3 tbl, 57 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF AND METHOD FOR TREATMENT OF CYTOKINE-MEDIATED DISEASE | 2000 |
|
RU2298008C2 |
COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | 2000 |
|
RU2242474C2 |
DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE-1-YL-UREA AND THEIR USE IN TREATMENT, INTER ALIA, DISEASES OF RESPIRATORY TRACT | 2011 |
|
RU2586333C1 |
KINASE INHIBITORS | 2012 |
|
RU2623734C9 |
IMMUNOMODULATORY AZALIDES BASED ON UREA | 2021 |
|
RU2811591C1 |
NEW PHTHALAZINONE DERIVATIVES AS AURORA A KINASE INHIBITORS | 2005 |
|
RU2397166C2 |
COMPOUNDS AND COMPOSITIONS AS CANNABINOID RECEPTOR 1 INHIBITORS | 2005 |
|
RU2431635C2 |
UREA COMPOUND, A METHOD FOR PRODUCTION THEREOF AND MEDICAL USE THEREOF | 2017 |
|
RU2741596C2 |
PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
NEW ANTICHOLINERGIC PREPARATIONS, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS PHARMACEUTICALS | 2003 |
|
RU2325388C2 |
Authors
Dates
2003-12-27—Published
1999-12-09—Filed